The Retinitis Pigmentosa market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Retinitis Pigmentosa pipeline products will significantly revolutionize the Retinitis Pigmentosa market dynamics.
DelveInsight’s “Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Retinitis Pigmentosa, historical and forecasted epidemiology as well as the Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Retinitis Pigmentosa market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Retinitis Pigmentosa market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Retinitis Pigmentosa Market Insights
Some of the key facts of the Retinitis Pigmentosa Market Report:
-
The Retinitis Pigmentosa market size was valued at USD 392.42 Million in the year 2020 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
In December 2023, Laboratoires Théa obtained two developing antisense oligonucleotide (AON) therapies targeting inherited retinal disorders from ProQR Therapeutics.
-
In August 2023, MeiraGTx disclosed the completion of enrollment for the Phase III LUMEOS clinical trial evaluating botaretigene sparoparvovec as a treatment for X-linked retinitis pigmentosa (XLRP).
-
In 2023, there were approximately 274,000 prevalent cases of retinitis pigmentosa across the 7MM, and this number is projected to rise in the forecast period.
-
In the 7MM, nonsyndromic retinitis pigmentosa is more common than syndromic retinitis pigmentosa, with approximately 187,000 cases reported in 2023.
-
Key Retinitis Pigmentosa Companies: SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc, Coave Therapeutics, jCyte, Nightstar Therapeutics, ReNeuron, and others
-
Key Retinitis Pigmentosa Therapies: CTx-PDE6b, jCell, AAV8-RPGR, BIIB112, Human retinal progenitor cells (hrpc) cell, and others
-
The Retinitis Pigmentosa epidemiology based on gender analyzed that a higher percentage of diagnosed prevalence was observed for males, in comparison to females, except Japan, where females occupy a larger patient pool than males
Retinitis Pigmentosa Overview
Retinitis pigmentosa (RP) is a group of inherited eye disorders characterized by the breakdown and loss of cells in the retina, the light-sensitive tissue lining the back of the eye. This condition causes gradual vision loss, typically starting with difficulty seeing at night or in low light, followed by a narrowing of the visual field (tunnel vision) and eventual loss of central vision.
Get a Free sample for the Retinitis Pigmentosa Market Report:
https://www.delveinsight.com/report-store/retinitis-pigmentosa-market
Retinitis Pigmentosa Market
The dynamics of the Retinitis Pigmentosa market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
Retinitis Pigmentosa Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Retinitis Pigmentosa Epidemiology Segmentation:
The Retinitis Pigmentosa market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Retinitis Pigmentosa
-
Prevalent Cases of Retinitis Pigmentosa by severity
-
Gender-specific Prevalence of Retinitis Pigmentosa
-
Diagnosed Cases of Episodic and Chronic Retinitis Pigmentosa
Download the report to understand which factors are driving Retinitis Pigmentosa epidemiology trends @ Retinitis Pigmentosa Epidemiological Insights
Retinitis Pigmentosa Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Retinitis Pigmentosa market or expected to get launched during the study period. The analysis covers Retinitis Pigmentosa market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Retinitis Pigmentosa Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Retinitis Pigmentosa Therapies and Key Companies
-
EA-2353: Endogena Therapeutics, Inc
-
OCU400-301: Ocugen
-
BS01: Bionic Sight LLC
-
CPK850: Novartis
-
AAV2/5-hPDE6B: eyeDNA Therapeutics
-
hRPC: ReNeuron Limited
-
SPVN06: SparingVision
-
RST-001: AbbVie
-
KIO-301: Kiora Pharmaceuticals
-
OCU400: Ocugen
-
QR-1123: ProQR Therapeutics
-
Ultevursen: ProQR Therapeutics
To know more about Retinitis Pigmentosa treatment, visit @ Retinitis Pigmentosa Medications
Retinitis Pigmentosa Market Strengths
-
AAVs have emerged as the predominant vectors for delivering genes of interest to target tissues with improved specificity, efficiency, and safety in the case of retinitis pigmentosa.
-
Gene therapy is advancing by leaps and bounds as it is more effective, less invasive, and relatively safer in the short term than retinal transplantation.
Retinitis Pigmentosa Market Opportunities
-
Alongside advances in cell and gene technologies, research advances in the fields of optogenetics and electronic retinal prostheses also represent encouraging progress for the treatment of retinitis pigmentosa and other inherited retinal dystrophies.
-
Cell therapies such as jCell by jCyte, once approved, will likely have a broad application as they are mutation-independent. Treatment can be initiated earlier as cell therapies do not require genetic testing.
Scope of the Retinitis Pigmentosa Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Retinitis Pigmentosa Companies: SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc, Coave Therapeutics, jCyte, Nightstar Therapeutics, ReNeuron, and others
-
Key Retinitis Pigmentosa Therapies: CTx-PDE6b, jCell, AAV8-RPGR, BIIB112, Human retinal progenitor cells (hrpc) cell, and others
-
Retinitis Pigmentosa Therapeutic Assessment: Retinitis Pigmentosa current marketed and Retinitis Pigmentosa emerging therapies
-
Retinitis Pigmentosa Market Dynamics: Retinitis Pigmentosa market drivers and Retinitis Pigmentosa market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Retinitis Pigmentosa Unmet Needs, KOL’s views, Analyst’s views, Retinitis Pigmentosa Market Access and Reimbursement
Discover more about therapies set to grab major Retinitis Pigmentosa market share @ Retinitis Pigmentosa market forecast
Table of Contents
1. Retinitis Pigmentosa Market Report Introduction
2. Executive Summary for Retinitis Pigmentosa
3. SWOT analysis of Retinitis Pigmentosa
4. Retinitis Pigmentosa Patient Share (%) Overview at a Glance
5. Retinitis Pigmentosa Market Overview at a Glance
6. Retinitis Pigmentosa Disease Background and Overview
7. Retinitis Pigmentosa Epidemiology and Patient Population
8. Country-Specific Patient Population of Retinitis Pigmentosa
9. Retinitis Pigmentosa Current Treatment and Medical Practices
10. Retinitis Pigmentosa Unmet Needs
11. Retinitis Pigmentosa Emerging Therapies
12. Retinitis Pigmentosa Market Outlook
13. Country-Wise Retinitis Pigmentosa Market Analysis (2020–2034)
14. Retinitis Pigmentosa Market Access and Reimbursement of Therapies
15. Retinitis Pigmentosa Market Drivers
16. Retinitis Pigmentosa Market Barriers
17. Retinitis Pigmentosa Appendix
18. Retinitis Pigmentosa Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
